|View printer-friendly version|
BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results
"In our first earnings report as a public company, we are pleased to provide the investment community with an update on our operations and insight into our clinical pipeline,” said Dr.
Dr. Huang added, “As a result of the IPO,
2016 and Recent Business Highlights
Plinabulin Mechanism of Action Update
Based on a three year collaborative effort with
Plinabulin is differentiated from other microtubule depolymerizing agents, such as the CA4P class, which cannot induce DC maturation or neutropenia prevention.
This groundbreaking finding was presented at the Keystone Meeting on
Clinical Programs Update
Plinabulin, for the Prevention of Chemotherapy-Induced Neutropenia
Plinabulin, in combination with docetaxel, a leading chemotherapy, has delivered encouraging results in the Phase 2 portion of a Phase 1/2 clinical trial conducted in
Based on encouraging Phase 2 results in which Plinabulin reduced severe neutropenia of docetaxel from 33% to less than 5% (p=0.0003), and discussions with the
Plinabulin, combination with docetaxel, for NSCLC
Expected Milestone Timeline
• Phase 3 Plinabulin and PD-1 Combo
• Phase 1 BPI-004 for neoantigen activation
• "molecular glue" agent using ubiquitination degradation pathways in collaboration with
Full Year 2016 Financial Highlights
Research and Development Expenses were
General and Administrative Expenses were
Net loss attributable to
Cash and cash equivalents were
Conference Call and Webcast Information
The Company will host an operational update conference call with the investment community on
A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the call will be available through May 12, 2017, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13659965. Also, a replay of the webcast will remain available on http://ir.beyondspringpharma.com for 30 days following the call.
Cautionary Note Regarding Forward-Looking Statements